Inhibition of CK2/ING4 Pathway Facilitates Non-Small Cell Lung Cancer Immunotherapy

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Programmed death ligand 1 (PD-L1) expression aids tumor immune escape, hindering anti-tumor immunotherapy.
• Casein kinase 2 (CK2) is a kinase implicated in tumor progression, but its role in immune escape is unclear.

Purpose of the Study:

• To investigate the effect of CK2 on non-small cell lung cancer (NSCLC) immune escape.
• To elucidate the molecular mechanism linking CK2, ING4, and PD-L1 in NSCLC.

Main Methods:

• Analysis of clinical NSCLC samples to correlate CK2 and ING4 expression.
• In vitro experiments to study CK2-mediated phosphorylation and ubiquitination of ING4.
• Assessment of T cell activity and tumor immune escape in response to CK2 modulation.
• Evaluation of combined CK2 inhibitor and PD-1 antibody therapy in preclinical models.

Main Results:

• ING4 induces PD-L1 degradation, enhancing T cell activity and inhibiting NSCLC immune escape.
• High CK2 expression correlates with low ING4 levels in NSCLC.
• CK2 phosphorylates ING4 at S150, leading to its ubiquitination and degradation by JFK ubiquitin ligase.
• CK2 gene knockout stabilizes ING4, increases T cell activity, and inhibits NSCLC immune escape.
• Combined CK2 inhibition and PD-1 antibody therapy shows enhanced anti-tumor effects.

Conclusions:

• CK2 promotes NSCLC immune escape by targeting ING4 for degradation.
• Targeting CK2 represents a novel strategy to enhance anti-tumor immunotherapy in NSCLC.